Brought to you by 
ImaRx Therapeutics completes its IPO
31 Oct 2007
Executive Summary
After withdrawing its filing last year, ImaRx Therapeutics (pharmaceuticals for cardiovascular conditions) has now gone public through an IPO netting $12.3mm through the sale of 3mm common shares at $5 each; the company originally estimated a share price in the $6.50-7.50 range.
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ImaRx Therapeutics completes its IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice